2024MAY10: Our hosting provider is experiencing intermittent networking issues. We apologize for any inconvenience.

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Hai-Dong Zhu | Hai-Liang Li | Ming-Sheng Huang | Wei-Zhu Yang | Guo-Wen Yin | Bin-Yan Zhong | Jun-Hui Sun | Zhi-Cheng Jin | Jian-Jian Chen | Nai-Jian Ge | Wen-Bin Ding | Wen-Hui Li | Jin-Hua Huang | Wei Mu | Shan-Zhi Gu | Jia-Ping Li | Hui Zhao | Shu-Wei Wen | Yan-Ming Lei | Yu-Sheng Song | Chun-Wang Yuan | Wei-Dong Wang | Ming Huang | Wei Zhao | Jian-Bing Wu | Song Wang | Xu Zhu | Jian-Jun Han | Wei-Xin Ren | Zai-Ming Lu | Wen-Ge Xing | Yong Fan | Hai-Lan Lin | Zi-Shu Zhang | Guo-Hui Xu | Wen-Hao Hu | Qiang Tu | Hong-Ying Su | Chuan-Sheng Zheng | Yong Chen | Xu-Ya Zhao | Zhu-Ting Fang | Qi Wang | Jin-Wei Zhao | Ai-Bing Xu | Jian Xu | Qing-Hua Wu | Huan-Zhang Niu | Jian Wang | Feng Dai | Dui-Ping Feng | Qing-Dong Li | Rong-Shu Shi | Jia-Rui Li | Guang Yang | Hai-Bin Shi | Jian-Song Ji | Yu-E Liu | Zheng Cai | Po Yang | Yang Zhao | Xiao-Li Zhu | Li-Gong Lu | Gao-Jun Teng | CHANCE001 Investigators
Signal transduction and targeted therapy | 2023

There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4-11.0) versus 8.0 months (95% CI, 6.6-9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1-27.3] vs. 15.7 months [13.0-20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile.

Pubmed ID: 36750721 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


R Project for Statistical Computing (tool)

RRID:SCR_001905

Software environment and programming language for statistical computing and graphics. R is integrated suite of software facilities for data manipulation, calculation and graphical display. Can be extended via packages. Some packages are supplied with the R distribution and more are available through CRAN family.It compiles and runs on wide variety of UNIX platforms, Windows and MacOS.

View all literature mentions

PASS (tool)

RRID:SCR_005490

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 19, 2020.A program to align short sequences that has been developed with an innovative strategy to perform fast gapped and ungapped alignment onto a reference sequence. It supports several data formats and allows the user to modulate very finely the sensitivity of the alignments. The program is designed to handle huge amounts of short reads generated by ILLUMINA, SOLiD and Roche-454 technology. The optimization of the internal data structure and a filter based on precomputed short-word alignments allow the program to skip false positives in the extension phase, thus reducing the execution time without loss of sensitivity. The final alignment is performed by dynamic programming.

View all literature mentions